ImmuPharma plc (LON:IMM – Get Free Report) was up 9.3% during trading on Friday . The company traded as high as GBX 4.50 ($0.06) and last traded at GBX 3.94 ($0.05). Approximately 31,560,066 shares were traded during trading, an increase of 60% from the average daily volume of 19,683,289 shares. The stock had previously closed at GBX 3.60 ($0.04).
ImmuPharma Stock Performance
The company has a market cap of £16.39 million, a PE ratio of -393.60 and a beta of 1.53. The company has a 50 day simple moving average of GBX 1.75 and a two-hundred day simple moving average of GBX 1.73.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
- Five stocks we like better than ImmuPharma
- Using the MarketBeat Stock Split Calculator
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- What is Insider Trading? What You Can Learn from Insider Trading
- 3 Buy-and-Hold Stocks for Long-Term Growth
- Best Stocks Under $10.00
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
